Skip to main content

Sanofi Ventures — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

69
Companies
$4.2B
Total invested
$61.3M
Avg. check
15
Industries
Biotechnology 22Health Care 17Medical 13Therapeutics 12Pharmaceutical 5Biopharma 5+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 69
Epicrispr Biotechnologies
October 2026

Epicrispr Biotechnologies is a biotechnology enterprise that focuses on epigenetic engineering.

Biotechnology · South San Francisco$8.0M Grant
Q32 Bio
July 2026

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Biotechnology · Cambridge$200.0M Post-IPO Equity
Nura Bio
June 2026

Nura Bio is a biotechnology company that develops neuroprotective therapies for neurological disorders.

Biotechnology · South San Francisco$73.8M Series B
Bionyra
June 2026

Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for severe immune-mediated inflammation.

Paris$165.0M Series A
Memento Medicines
June 2026

Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.

Biotechnology · Chester$93.0M Series A
BranchLab
May 2026

The AI Platform for Pharma Commercialization

Artificial Intelligence (AI) · New York$28.8M Series A
Click Therapeutics
April 2026

Click Therapeutics develops and commercializes software as prescription medical treatments designed to address unmet healthcare needs.

Biotechnology · New York$50.0M Series D
QuantX Biosciences
February 2026

QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products.

Biotechnology · Princeton$85.0M Series B
Muna Therapeutics
January 2026

Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Biopharma · Copenhagen$1.0M Grant
Lifordi Immunotherapeutics
November 2025

Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.

Biotechnology · Burlington$42.0M Venture - Series Unknown
T-Therapeutics
November 2025

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.

Biotechnology · Cambridge$32.0M Series A
Zag Bio
October 2025

Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.

Biopharma · Cambridge$80.0M Series A
ReCode Therapeutics
September 2025

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Biopharma · Dallas$29.4M Debt Financing
Character Biosciences
September 2025

Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.

Artificial Intelligence (AI) · Jersey City$17.0M Series B
Eligo Bioscience
May 2025

Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals.

Biotechnology · Paris$5.0M Grant
Granite Bio
April 2025

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

Biotechnology · Basel$70.0M Series B
Glycomine
April 2025

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

Biotechnology · San Carlos$115.0M Series C
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Latigo Biotherapeutics
March 2025

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

Biotechnology · Thousand Oaks$150.0M Series B
Curevo
March 2025

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Biopharma · Bothell$110.0M Series B
Atalanta Therapeutics
January 2025

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

Biotechnology · Boston$97.0M Series B
NextPoint Therapeutics
February 2024

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.

Biotechnology · Cambridge$42.5M Series B
Sudo Biosciences
February 2024

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

Biopharma · Carmel$30.0M Series B
i2o Therapeutics
August 2023

I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies.

Biotechnology · Allston$46.0M Series A

Where Sanofi Ventures invests

Biotechnology22
Health Care17
Medical13
Therapeutics12
Pharmaceutical5
Biopharma5

About Sanofi Ventures's portfolio

How many companies has Sanofi Ventures invested in?▸

Sanofi Ventures has invested in 69 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Sanofi Ventures invest in?▸

Sanofi Ventures's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 15 different industry categories.

What is Sanofi Ventures's largest investment?▸

Among tracked funding rounds, Q32 Bio received $200.0M in a Post-IPO Equity round. Sanofi Ventures's total known invested capital is $4.2B.

What is the average investment size for Sanofi Ventures?▸

Sanofi Ventures's average investment size is $61.3M across its portfolio of 69 companies.

What are Sanofi Ventures's most recent investments?▸

Recent Sanofi Ventures portfolio additions include Epicrispr Biotechnologies, Q32 Bio, Nura Bio, Bionyra, Memento Medicines. These companies were founded in 2020 or later.

Reach the founders behind these 69 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →